Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

The MET inhibitor INC-280 restored sensitivity to erlotinib and promoted apoptosis in non–small-cell lung cancer models rendered resistant to erlotinib by hepatocyte growth factor. BACKGROUND: Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in non–smal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lung Cancer
Main Authors: Lara, Matthew S., Holland, William S., Chinn, Danielle, Burich, Rebekah A., Lara, Primo N., Gandara, David R., Kelly, Karen, Mack, Philip C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837026/
https://ncbi.nlm.nih.gov/pubmed/28038979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2016.11.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados